Previous 10 | Next 10 |
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present in a fireside chat the Morgan Stanley Virtual 19th Annual Global Healthcare Conference bein...
Biodesix, Inc. (Nasdaq: BDSX). Today Biodesix announced that the Accreditation Committee of the College of American Pathologists (CAP) and British Standards Institute (BSI) on behalf of International Organization for Standardization (ISO) recently awarded both CAP accreditation and ...
Biodesix shares fall (BDSX -25.7%) a day after reporting second-quarter results that missed Wall Street estimates, and provided a cash position update. The company's quarterly revenue nearly tripled to $11.9M, but fell short of estimates by $9.25M. Biodesix also reported net loss than widened...
Gainers: CohBar (NASDAQ:CWBR) +42%, Allied Healthcare Products AHPI +24%, Doximity DOCS +22%, Orphazyme (NASDAQ:ORPH) +13%, Fulcrum Therapeutics FULC +13%. Losers: Biodesix (NASDAQ:BDSX) -19%, Inari Medical (NASDAQ:NARI) -16%, Berkeley Li...
Image source: The Motley Fool. Biodesix, Inc. (NASDAQ: BDSX) Q2 2021 Earnings Call Aug 10, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Biodesix, Inc. (BDSX) Q2 2021 Earnings Call Transcript
Biodesix, Inc. (BDSX) Q2 2021 Earnings Conference Call August 10, 2021 04:30 PM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley Brian Weinstein...
Second Quarter 2021 Revenue of $11.9 Million Increased 180% and Lung Diagnostic Revenue of $4.8 Million Increased 109% over Second Quarter 2020 Announcing Acceleration of the Launch of the 72-hour liquid NGS Test to Early First Quarter 2022 Conference Call and Webcast ...
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the Canaccord Genuity 41st Annual Growth Conference being held virtually August 10-12, 2...
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the second quarter ended June 30, 2021 after the close of trading on Tuesday, August 10. Biodesix’s manag...
Biodesix went public late in 2020 as investors had real concerns from the start. Shares did really well since the offering as the company reported strong revenue numbers driven by Covid-19, although it did not translate into earnings yet. This makes me cautious, as shares have fal...
News, Short Squeeze, Breakout and More Instantly...
Awarding Excellence in Company Culture Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, is honored to announce it has been named to Inc. Magazine’s Best Workplaces list . The ranking is a result of a comprehensive, data-driven measurement pro...
Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, will participate in two upcoming investor conferences: William Blair 44 th Annual Growth Stock Conference Presentation and 1x1...
Data highlights ability of the Nodify XL2 test to identify benign nodules in patients with emphysema Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced that new data will be presented today at the 2024 American Thoracic Society ...